MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced the close of an oversubscribed $67 million Series B financing. The financing was co-led by new investors Ascenta Capital and Woodline Partners LP, with significant participation from existing investors Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, and Eli Lilly and Company.

加利福尼亚州门洛帕克（商业新闻短讯）--OrsoBio，Inc.（“OrsoBio”或“该公司”）是一家临床阶段的生物制药公司，开发肥胖症和肥胖症相关疾病的治疗方法，今天宣布结束超额认购的6700万美元B系列融资。此次融资由新投资者Ascenta Capital和Woodline Partners LP共同牵头，现有投资者Samsara Biocapital、Longitude Capital、Enavate Sciences、NuevaBio和Eli Lilly and Company参与了此次融资。

In conjunction with the financing, Evan Rachlin, MD, Co-Founder and Managing Partner of Ascenta Capital, has joined the OrsoBio Board of Directors. Proceeds from the financing will be used to accelerate development of the Company’s mitochondrial protonophore portfolio for the treatment of obesity and associated metabolic disorders..

在融资方面，Ascenta Capital联合创始人兼管理合伙人Evan Rachlin医学博士加入了OrsoBio董事会。融资收益将用于加速公司线粒体质子载体投资组合的开发，用于治疗肥胖和相关代谢紊乱。。

Obesity affects more than 40% of U.S. adults and leads to a range of adverse health outcomes including type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatohepatitis (MASH). Obesity is caused by an imbalance between energy intake and energy expenditure that leads to excess adiposity.

肥胖影响超过40%的美国成年人，并导致一系列不良健康后果，包括2型糖尿病，心血管疾病和代谢功能障碍相关的脂肪性肝炎（MASH）。肥胖是由能量摄入和能量消耗之间的不平衡引起的，导致过度肥胖。

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized weight management by reducing caloric intake, they may cause loss of lean mass and metabolic adaptations that reduce energy expenditure..

尽管胰高血糖素样肽-1受体激动剂（GLP-1 RAs）通过减少热量摄入而彻底改变了体重管理，但它们可能会导致瘦体重减少和代谢适应，从而减少能量消耗。。

Mitochondrial protonophores directly increase energy expenditure and may represent the ideal means to complement the metabolic benefits of GLP-1 RAs. In preclinical studies, mitochondrial protonophores developed by OrsoBio led to weight loss, preserved lean mass, and improved insulin sensitivity. Further, when these potential therapies were used in combination with a GLP-1 RA, additional weight and fat mass loss were observed, without significant effects on lean mass.

线粒体质子团直接增加能量消耗，可能是补充GLP-1 RAs代谢益处的理想手段。在临床前研究中，OrsoBio开发的线粒体质子团导致体重减轻，保持瘦体重，并改善胰岛素敏感性。此外，当这些潜在的疗法与GLP-1 RA联合使用时，观察到额外的体重和脂肪量减少，而对瘦体重没有显着影响。

These benefits were sustained with continued protonophore therapy following GLP-1 RA discontinuation.1.

GLP-1 RA停药后继续质子载体治疗可以维持这些益处。

TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore under evaluation in a 12-week, Phase 1b clinical trial in patients living with obesity (NCT05822544). In a prior Phase 1 study in healthy subjects, TLC-6740 was safe, well tolerated, and caused dose-dependent increases in energy expenditure and improvements in lipids and markers of insulin resistance.

TLC-6740是一种新型的口服肝靶向线粒体质子载体，正在肥胖症患者的12周1b期临床试验中进行评估（NCT05822544）。在健康受试者的先前1期研究中，TLC-6740安全，耐受性良好，并引起能量消耗的剂量依赖性增加以及脂质和胰岛素抵抗标志物的改善。

Additional Phase 1b and Phase 2a studies of TLC-6740 in patients with obesity and type 2 diabetes, including those on a GLP-1 RA, will initiate in the coming months..

未来几个月将开始对肥胖和2型糖尿病患者（包括GLP-1 RA患者）进行TLC-6740的其他1b期和2a期研究。。

IND-enabling studies for two additional novel protonophores (TLC-1180 and TLC-1235) with unique attributes compared to TLC-6740, including greater systemic distribution, are expected to be completed in 2025. TLC-1180 is a potent, long-acting mitochondrial protonophore that is suitable for weekly oral or subcutaneous administration.

与TLC-6740相比，具有独特属性的另外两种新型质子载体（TLC-1180和TLC-1235）的IND研究有望在2025年完成，包括更大的系统分布。TLC-1180是一种有效的长效线粒体质子载体，适用于每周口服或皮下给药。

TLC-1235 is a controlled-release mitochondrial protonophore (CRMP) that has shown metabolic benefits across a range of models and species.2.

TLC-1235是一种控释线粒体质子载体（CRMP），已在一系列模型和物种中显示出代谢益处。

'We welcome Ascenta Capital and Woodline Partners to OrsoBio and appreciate their support and that of our existing investors. These resources enable us to continue advancing our portfolio of mitochondrial protonophores and other potential therapies to address the burden of obesity and obesity-associated diseases,” said Mani Subramanian, MD, PhD, CEO and Founder of OrsoBio.

“我们欢迎Ascenta Capital和Woodline合作伙伴加入OrsoBio，并感谢他们和现有投资者的支持。这些资源使我们能够继续推进线粒体质子载体和其他潜在疗法的组合，以解决肥胖和肥胖相关疾病的负担，”OrsoBio首席执行官兼创始人Mani Subramanian博士说。

“We believe that the future of obesity treatment will include GLP-1 RA-based combinations; this financing will enable us to build the scientific and clinical foundations to support our protonophores as components of these regimens.”.

“我们相信肥胖治疗的未来将包括基于GLP-1 RA的组合；这笔资金将使我们能够建立科学和临床基础，以支持我们的质子载体作为这些方案的组成部分。”。

'OrsoBio’s novel mechanisms hold promise to enhance weight loss, improve metabolic function, and preserve lean muscle mass,” said Evan Rachlin, MD, Co-Founder and Managing Partner of Ascenta Capital. “These medicines could one day complement GLP-1 RA-based approaches and expand the long-term health benefits of these treatments.

Ascenta Capital联合创始人兼管理合伙人、医学博士埃文·拉克林（EvanRachlin）表示：“奥索比奥（OrsoBio）的新机制有望增强体重减轻，改善代谢功能，保持瘦肌肉质量。”。。

We look forward to partnering with the world-class team at OrsoBio to help bring these extraordinary medicines to patients.”.

我们期待着与OrsoBio的世界级团队合作，帮助将这些非凡的药物带给患者。”。

OrsoBio’s portfolio of compounds in clinical development also includes TLC-3595, an ACC2 inhibitor, currently in a Phase 2a study for the treatment of type 2 diabetes, and TLC-2716, a liver X receptor (LXR) inverse agonist currently in a Phase 2a study for severe hypertriglyceridemia and MASH.

OrsoBio在临床开发中的化合物组合还包括TLC-3595（一种ACC2抑制剂），目前正在进行治疗2型糖尿病的2a期研究，以及TLC-2716（一种肝X受体（LXR）反向激动剂），目前正在进行严重高甘油三酯血症和MASH的2a期研究。

About OrsoBio, Inc.

关于Orsobio，Inc。

OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.

OrsoBio，Inc.是一家私营的临床阶段生物制药公司，致力于开发治疗肥胖和肥胖相关疾病的疗法，包括2型糖尿病，MASH和严重血脂异常。OrsoBio目前有四个临床和临床前开发项目，其中包括一流的化合物，可解决能量代谢的中心途径。

For more information, please visit www.orsobio.com..

有关更多信息，请访问www.orsobio.com。。

____________________________

____________________________

1 Data accepted for presentation at ObesityWeek® 2024.

1数据被接受在ObesityWeek®2024上展示。

2 Perry RJ, et al. Science 2015 (PMID: 25721504); Goedeke L, et al. Mol Metab 2021 (PMID: 33545391).

2 Perry RJ等人，《科学》2015（PMID:25721504）；Goedeke L等人，《分子代谢2021》（PMID:33545391）。